Objectives: To determine the mortality rate secondary to bla KPC Klebsiella pneumoniae (KPC/Kp) bacteraemia, compared with that from ESBL-producing K. pneumoniae (ESBL/Kp) bacteraemia, and to determine associated risk factors.
Introduction
During the last decade, infections due to carbapenemaseproducing Enterobacteriaceae and Klebsiella pneumoniae (KPC/Kp) have been reported from many countries 1 -4 and have become endemic in all Israeli hospitals. 5 -10 Several studies have examined the mortality rate of patients with K. pneumoniae infection and risk factors for infection with and death from carbapenem-resistant K. pneumoniae 2 -4,9 -13 and the influence of isolation implementation on the spread of bacteria. 14 In most studies that assessed mortality the sample size was small. 2 -4,9 -13 In others there was a mixture of specimens, such as blood, urine, sputum and surgical wounds, 3, 9 compromising the ability to draw valid conclusions. In several studies the control group did not adequately match the study group, making it difficult to isolate various factors that might influence the outcome of infection.
The primary aim of this study was to determine the mortality rate of hospitalized patients with KPC/Kp bacteraemia compared with that of a control group with carbapenem-susceptible ESBL-producing K. pneumoniae (ESBL/Kp) bacteraemia. A secondary object was to determine risk factors for dying with KPC/Kp sepsis compared with ESBL/Kp sepsis.
Methods
The study was conducted in Shaare Zedek Medical Center, a 1000 bed university-affiliated hospital.
Patient identification
We used the microbiology laboratory database to identify all patients who had bloodstream infection (BSI) with K. pneumoniae, with focus on ESBL-producing Klebsiella and carbapenem-resistant Klebsiella. 
Microbiology
Our microbiology laboratory has tested Enterobacteriaceae for susceptibility to imipenem since 1997 and to ertapenem since 2003. Imipenem susceptibility testing was changed to meropenem in 2007. Carbapenem resistance in K. pneumoniae isolates was defined as resistance to two or more carbapenems (of which one was always ertapenem). Confirmation of KPC carbapenemase resistance of K. pneumoniae was done by PCR and with the modified Hodge test (MHT) according to the CLSI protocol. 15 The specific type of bla KPC gene was not determined, while the RT-PCR is gene specific. 15 In Israel the bla KPC strains are clonal and have been characterized as KPC3 by the Ministry of Health Laboratory. 16 In the control isolates, the ESBL mechanism was determined by double disc diffusion, according to CLSI M100-S24 guidelines. 17 We detected 76 patients who had bacteraemia with carbapenemresistant K. pneumoniae by ertapenem/meropenem resistance. Of these 76 bacteria, 23 were listed as MHT and PCR positive, as they were isolated after June 2008, when these tests had become routine. The remaining 53 bacteria were removed from 2808C storage, cultured and tested by PCR and MHT. Of these 53, 3 bacteria did not grow after .6 years of remaining frozen and 5 other bacteria were PCR and MHT negative despite resistance to carbapenems. Therefore, the study group included 68 KPC/Kp-proven patient-unique bacteria, i.e. from each patient only 1 isolate was included. This study group was matched at a rate of 1:2 to a control group of 136 patients with ESBL/Kp, i.e. 2 ESBL/Kp cases for each case of KPC/Kp, matched by year of isolation, age decade and gender. The patient files were retrieved and demographic, clinical and laboratory data were extracted. The severity of illness and probability of dying were calculated for each patient using the mortality probability model (MPM) score, which does not require acid -base balance data as these are not available for many medical patients. 18 
Definitions
An empirical antimicrobial treatment was defined as appropriate if it included at least one drug displaying in vitro activity against the isolated strain. The major endpoint was in-hospital mortality.
Statistical methods
The data were entered into an application written on Epi-Info (CDC, USA) version 3.5.4. We used Epi-Info and Win-Pepi (version 11.39) for statistical analysis. For categorical variables we used the x 2 test or Fisher's exact test, and for continuous variables the t-test or non-parametric tests. All tests were performed with strict matching as required from the study structure, and two-tailed P values were always taken. A P value ,0.05 was defined as significant. To perform conditional logistic regression analysis in a matched 1:2 ratio we used Stata version 12 software (StataCorp, USA). For the logistic regression models we took only the variables that were significant or close to significant (P, 0.08) in the univariate analysis, but only after co-linear examination between every pair of these variables. The conduct of the study was approved by the hospital's internal review board. Informed consent was waived because of the retrospective observational nature of the study.
Results
The computer database of the microbiology laboratory held information on 480 patient-unique isolates of KPC/Kp or ESBL/Kp bacteraemia, comprising 76 patient-unique isolates of KPC/Kp and 404 of ESBL/Kp. The first KPC/Kp bacteraemia case in our hospital was diagnosed in June 2006 ( Figure S1 , available as Supplementary data at JAC Online). Baseline demographic and clinical data on the included 68 study and 136 control patients are shown in Table 1 . Patients with ESBL/Kp had a lower mean systolic pressure and a higher rate of bladder catheterization, while a higher incidence of acute renal failure was found in KPC/Kp patients. The higher rate of KPC/Kp compared with ESBL/Kp detection by surveillance culture (25% and 4%, respectively) derives from the ongoing surveillance programme for KPC/Kp detection; ESBL/Kp surveillance is carried out sporadically only.
Outcome of hospitalization is shown in Table 2 . In total, 54 of 136 patients (40%) with ESBL/Kp bacteraemia died, compared with 44 of 68 patients (65%) with KPC/Kp bacteraemia (P ¼ 0.0008; Figure S1 ). In addition, patients who survived KPC/Kp sepsis were discharged in good functional state in only 16% of cases compared with 32% of patients who survived ESBL/Kp sepsis (P¼0.012). Risk factors for mortality are shown in Table S1 . Logistic regression analyses carried out in different models found that congestive heart failure (P,0.05), acute renal failure (P,0.05) and especially KPC/Kp bloodstream infection (compared with ESBL/Kp bacteraemia) (P,0.001) were independent risk factors for death.
Discussion
The 68 patients in this study all had bacteraemia and the organism was identified as KPC/Kp with the latest laboratory methods. 15 We chose a control group of patients with bacteraemia due to ESBL/Kp, assuming that both groups had similar rates of nosocomial source and comorbidity, similar to the study by Ben-David et al.
14 This assumption was subsequently confirmed in the baseline data ( Table 1 ). The use of two control patients with ESBL/Kp bacteraemia for each study patient with KPC/Kp bacteraemia produced in our view the cleanest dataset to answer the study question. To our knowledge, ours is so far the largest singlecentre published cohort of KPC/Kp bacteraemia (Table S2) . 19 In addition, because all strains were kept at 2808C, we were able to perform confirmation of the genetic mechanism of carbapenem resistance. Therefore, our study group was very homogeneous because all study patients had the same type of KPC/Kp strain.
This study indicates that the in-hospital mortality of patients with KPC/Kp bacteraemia was 65% compared with 40% in the ESBL/Kp cohort; hence, the attributable mortality rate was 25%. This difference was also found highly significant (P, 0.001) in the multivariate analysis and therefore appears to an independent risk factor for death. Possible explanations for this difference include increased virulence of KPC/Kp bacteria compared with ESBL/Kp, or inefficiency of antibiotic treatment. In our study, 30/68 (44%) of KPC/Kp patients received initial appropriate treatment compared with 54/136 (40%) of ESBL/Kp patients (statistically non-significant), worrisomely low percentages. This led to adaptation of the standard protocol for empirical treatment for serious nosocomial infections and more liberal empirical use of polymyxin (colistin). However, sub-analysis of mortality rates according to appropriateness of initial treatment revealed that the death rate of KPC/Kp patients was significantly higher than that of ESBL/Kp patients, independently of appropriateness of initial treatment. For KPC/Kp patients, the death rate was 67% and 64% for subgroups whose initial treatment was appropriate and inappropriate, respectively. This suggests that the very high mortality of KPC/Kp sepsis is related to the organism and associated virulence.
Fraenkel-Wandel et al.
Our study has several limitations. First, the study group included 68 patients, not a large number, but so far this is the largest single-centre cohort in the literature, to our knowledge. A recently published large multicentre study from Italy confirms the high mortality rate associated with KPC/Kp bacteraemia. 20 Second, the similarity of the patient and control groups prevented detection of further risk factors for death, in addition to KPC/Kp and heart and renal failure. Choice of b-lactam-susceptible K. pneumoniae as the control would probably have led to other risk factors, similar to other studies. In our view the advantage of the similarity of the groups by far outweighs the disadvantage.
In conclusion, in this retrospective single-centre study of patients with KPC/Kp bacteraemia it has been unequivocally demonstrated that KPC/Kp is an independent risk factor for mortality, not related to appropriateness of initial antibiotic therapy. This finding, as well as the paucity of therapeutic options, underlines the importance of surveillance for KPC/Kp carriage for patients at risk and adherence to strict isolation of patients found to be carriers. Fraenkel-Wandel et al.
